Goldman Sachs Group »

Karyopharm Therapeutics shares owned by Goldman Sachs Group

Quarter-by-quarter ownership of Karyopharm Therapeutics (KPTI) shares owned by Goldman Sachs Group from 13F filings

Historical chart of Goldman Sachs Group investment in Karyopharm Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics held by Goldman Sachs Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics by Goldman Sachs Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $163k 25k 6.54
2025-03-31 $319k 85k 3.74

More positions owned by Goldman Sachs Group

Nvidia Corporation CMN (NVDA)
Spdr S&p 500 Etf Tr CMN (SPY)
Microsoft Corp CMN (MSFT)
Apple CMN (AAPL)
Invesco Qqq Tr CMN Put Option (QQQ)
Tesla CMN (TSLA)
Amazon CMN (AMZN)
Meta Platforms CMN (META)
Alphabet CMN (GOOGL)
Broadcom CMN (AVGO)
Ishares Tr CMN (IVV)
Ishares Tr CMN Put Option (IWM)
Vanguard Index Fds CMN (VOO)
Ishares Tr CMN Put Option (HYG)
Jpmorgan Chase & Co. CMN (JPM)

View all positions for Goldman Sachs Group

Top funds holding Karyopharm Therapeutics

T. Rowe Price Investment Management
Adage Capital Partners GP
Vanguard Group
Susquehanna International
BlackRock
Affinity Asset Advisors
Catalio Capital Management
Avidity Partners Management
Marshall Wace
CAM Group Holding A/S
Geode Capital Management
Citadel Advisors
Group One Trading
Renaissance Technologies
UBS Group

View all funds holding Karyopharm Therapeutics